Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

The two stocks have been trending in different directions for months. Here's what that says about the broader market.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Bank of America (BofA) on Friday lowered its price target for Novo Nordisk (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...